Women's Infertility Therapeutics - Pipeline Assessment and Market Forecasts to 2018
NEW YORK, Sept. 12, 2011 /PRNewswire/ --Reportlinker.com announces that a new market research report is available in its catalogue:
Women's Infertility Therapeutics - Pipeline Assessment and Market Forecasts to 2018
http://www.reportlinker.com/p0611548/Women's-Infertility-Therapeutics---Pipeline-Assessment-and-Market-Forecasts-to-2018.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Hardware,_Home_Improvement_&_Furnishing_Stores
Women's Infertility Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Summary
GlobalData, the industry analysis specialist, has released its new report, "Women's Infertility Therapeutics - Pipeline Assessment and Market Forecasts to 2018". The report is an essential source of information and analysis on the global Women's Infertility Therapeutics market. The report identifies the key trends shaping and driving the global Women's Infertility Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Women's Infertility Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.
Scope
The report provides information on the key drivers and challenges of the Women's Infertility Therapeutics market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Women's Infertility Therapeutics market revenues data from 2005 to 2009, forecast for eight years to 2017.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Women's Infertility Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Women's Infertility Therapeutics market.
- Analysis of key recent licensing and partnership agreements in Women's Infertility Therapeutics market
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Women's Infertility Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Women's Infertility Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What's the next big thing in the global Women's Infertility Therapeutics market landscape? – Identify, understand and capitalize.
1 Table of contents
1 Table of contents 2
1.1 List of Tables 4
1.2 List of Figures 5
2 Women's Infertility Therapeutics - Introduction 6
2.1 Overview 6
2.1.1 Quality of Life 7
2.2 Epidemiology 7
2.3 Etiology and Pathophysiology 7
2.4 Signs and Symptoms 9
2.5 Diagnosis 9
2.6 Treatment and Management 10
2.7 GlobalData Pipeline Report Guidance 12
3 Women's Infertility Therapeutics - Market Characterization 13
3.1 Overview 13
3.2 Women's Infertility Therapeutics Market Size (2005-2010) - Global 13
3.3 Women's Infertility Therapeutics Market Forecast (2010-2018) - Global 14
3.4 Women's Infertility Therapeutics Market Size (2005-2010) - The US 15
3.5 Women's Infertility Therapeutics Market Forecast (2010-2018) - The US 16
3.6 Women's Infertility Therapeutics Market Size (2005-2010) - France 17
3.7 Women's Infertility Therapeutics Market Forecast (2010-2018) - France 18
3.8 Women's Infertility Therapeutics Market Size (2005-2010) - Germany 19
3.9 Women's Infertility Therapeutics Market Forecast (2010-2018) - Germany 20
3.10 Women's Infertility Therapeutics Market Size (2005-2010) - Italy 21
3.11 Women's Infertility Therapeutics Market Forecast (2010-2018) - Italy 22
3.12 Women's Infertility Therapeutics Market Size (2005-2010) - Spain 23
3.13 Women's Infertility Therapeutics Market Forecast (2010-2018) - Spain 24
3.14 Women's Infertility Therapeutics Market Size (2005-2010) - The UK 25
3.15 Women's Infertility Therapeutics Market Forecast (2010-2018) - The UK 26
3.16 Women's Infertility Therapeutics Market Size (2005-2010) - Japan 27
3.17 Women's Infertility Therapeutics Market Forecast (2010-2018) - Japan 28
3.18 Drivers and Barriers for the Women's Infertility Therapeutics Market 29
3.18.1 Drivers for the Women's Infertility Therapeutics Market 29
3.18.2 Barriers for the Women's Infertility Therapeutics Market 29
3.19 Opportunity and Unmet Need 30
3.20 Key Takeaway 30
4 Women's Infertility Therapeutics - Competitive Assessment 31
4.1 Overview 31
4.1.1 Strategic Competitor Assessment 31
4.2 Women's Infertility Market, Marketed Products Profile 32
4.2.1 Ovidrel (choriogonadotropin alfa) 32
4.2.2 Gonal-f (follitropin alfa) 33
4.2.3 Cetrotide (cetrorelix acetate) 36
4.2.4 Luveris (lutropin alfa) 38
4.2.5 Elonva (corifollitropin alfa injection) 40
4.3 Key Takeaway 41
5 Women's Infertility Therapeutics - Pipeline Assessment 42
5.1 Overview 42
5.2 Strategic Pipeline Assessment 42
5.3 Women's Infertility Therapeutics Pipeline - Pipeline by Phases of Development 42
5.3.1 Women's Infertility Therapeutics - Phase III and NDA Filed Pipeline 42
5.3.2 Women's Infertility Therapeutics - Phase II Pipeline 43
5.3.3 Women's Infertility Therapeutics - Phase I Pipeline 43
5.3.4 Women's Infertility Therapeutics - Preclinical and Discovery Pipeline 43
5.4 Women's Infertility Therapeutics Market - Clinical Pipeline by Mechanism of Action 44
5.5 Technology Trends Analytical Framework 45
5.6 Women's Infertility Therapeutics - Promising Drugs Under Clinical Development 46
5.7 Molecule Profiles for Promising Drugs Under Clinical Development 47
5.7.1 Progesterone Vaginal Ring 47
5.7.2 DA-3801 (rFSH) 47
5.7.3 Afolia (follitropin alfa) 48
5.8 Key Takeaway 48
6 Women's Infertility Therapeutics - Clinical Trials Mapping 49
6.1 Clinical Trials by Region/Country (the US, EU5 and Japan) 49
6.2 Clinical Trials by Phase 50
6.3 Clinical Trials by Trial Status 51
6.4 Prominent Sponsors 52
6.5 Top Companies Participating in Women's Infertility Therapeutics Clinical Trials 54
7 Women's Infertility Therapeutics - Strategic Assessment 55
7.1 Key Events Impacting the Future Market 55
7.2 Women's Infertility Therapeutics - Implications for Future Market 55
8 Women's Infertility Therapeutics - Future Players 57
8.1 Introduction 57
8.2 Merck and Co., Inc. 58
8.2.1 Company Overview 58
8.2.2 Business Description 58
8.2.3 Women Infertility Pipeline 59
8.3 Dong-A Pharmaceutical Co. Ltd. 60
8.3.1 Company overview 60
8.3.2 Business Description 60
8.3.3 Women's Infertility Pipeline 61
8.4 Teva Pharmaceutical Industries Limited 62
8.4.1 Company Overview 62
8.4.2 Business description 62
8.4.3 Women's Infertility Pipeline 63
8.5 Gedeon Richter Plc 64
8.5.1 Overview 64
8.5.2 Business Description 64
8.5.3 Women's Infertility Pipeline 65
9 Licensing and Partnership Deals 66
10 Global Women's Infertility Market - Appendix 68
10.1 Market Definitions 68
10.2 Abbreviations 68
10.3 Research Methodology 69
10.3.1 Coverage 69
10.3.2 Secondary Research 69
10.3.3 Forecasting 70
10.3.4 Primary Research 72
10.3.5 Expert Panels 72
10.4 Contact Us 72
10.5 Disclaimer 72
10.6 Bibliography 73
1.1 List of Tables
Table 1: Types of Women's Infertility 7
Table 2: Women's Infertility Therapeutics, Global, Market Revenue ($m), 2005-2010 13
Table 3: Women's Infertility Therapeutics, Global, Revenue Forecasts ($m), 2010-2018 14
Table 4: Women's Infertility Therapeutics Market, The US, Revenue ($m), 2005-2010 15
Table 5: Women's Infertility Therapeutics Market, The US, Revenue ($m), 2010-2018 16
Table 6: Women's Infertility Therapeutics, France, Market Revenue ($m), 2005-2010 17
Table 7: Women's Infertility Therapeutics, France, Revenue Forecasts ($m), 2010-2018 18
Table 8: Women's Infertility Therapeutics, Germany, Market Revenue ($m), 2005-2010 19
Table 9: Women's Infertility Therapeutics, Germany, Revenue Forecasts ($m), 2010-2018 20
Table 10: Women's Infertility Therapeutics, Italy, Market Revenue ($m), 2005-2010 21
Table 11: Women's Infertility Therapeutics, Italy, Revenue Forecasts ($m), 2010-2018 22
Table 12: Women's Infertility Therapeutics, Spain, Market Revenue ($m), 2005-2010 23
Table 13: Women's Infertility Therapeutics, Spain, Revenue Forecasts ($m), 2010-2018 24
Table 14: Women's Infertility Therapeutics, the UK, Market Revenue ($m), 2005-2010 25
Table 15: Infertility Therapeutics, the UK, Revenue Forecasts ($m), 2010-2018 26
Table 16: Women's Infertility Therapeutics Market, Japan, Revenue ($m), 2005-2010 27
Table 17: Women's Infertility Therapeutics Market, Japan, Forecast ($m), 2010-2018 28
Table 18: Efficacy Outcomes of r-hCG in ART 32
Table 19: Ovulation and Clinical Pregnancy Rates by Treatment Group in Ovulation Induction 34
Table 20: Pregnancy Outcome by Treatment Group in Ovulation Induction 35
Table 21: Patient Ovulation and Clinical Pregnancy Rates by Treatment Group 35
Table 22: Pregnancy Outcome by Treatment Group in Ovulation Induction 35
Table 23: Pregnancy Outcome by Treatment Group in ART 36
Table 24: Pregnancy Outcome by Treatment Group in ART 36
Table 25: Results of Phase III Clinical Studies with Cetrotide 3mg in a Single Dose Regimen and 0.25mg in a Multiple Dose Regimen 37
Table 26: Follicular Development Rate 38
Table 27: Secondary Efficacy Parameters 39
Table 28: Follicular Development Rate 39
Table 29: Secondary Efficacy Parameters 39
Table 30: Cumulative Follicular Development Rate 40
Table 31: Primary Efficacy Variable 40
Table 32: Pregnancy Rate in the 150mcg Trial 41
Table 33: Women's Infertility Therapeutics - Phase III and NDA Filed Pipeline, 2011 42
Table 34: Women's Infertility Therapeutics - Phase II Pipeline, 2011 43
Table 35: Women's Infertility Therapeutics - Phase I Pipeline, 2011 43
Table 36: Women's Infertility Therapeutics - Discovery and Preclinical Pipeline, 2011 43
Table 37: Women's Infertility Therapeutics - Most Promising Drugs Under Clinical Development, 2011 46
Table 38: Women's Infertility Therapeutics - Clinical Trials by Country, 2011 49
Table 39: Women's Infertility Therapeutics - Clinical Trials by Phase, 2011 50
Table 40: Women's Infertility Therapeutics - Clinical Trials by Status, 2011 51
Table 41: Women Infertility Therapeutics - Prominent Sponsors, 2011 53
Table 42: Women's Infertility Therapeutics - Top Companies Participating in Therapeutics Clinical Trials, 2011 54
Table 43: Merck & Co., Inc. - Women's Healthcare Pipeline Products, 2011 59
Table 44: Merck & Co., Inc - Women's Infertility Pipeline Portfolio, 2011 59
Table 45: Dong-A Pharmaceutical Co., Ltd - Women's Health Pipeline Portfolio, 2011 61
Table 46: Dong-A Pharmaceutical Co., Ltd - Women's Infertility Pipeline Portfolio, 2011 61
Table 47: Teva Pharmaceutical Industries Limited - Women's Health Pipeline Portfolio, 2011 63
Table 48: Teva Pharmaceutical Industries Limited - Women's Infertility Pipeline Portfolio, 2011 63
Table 49: Gedeon Richter Plc - Women's Health Pipeline Portfolio, 2011 65
Table 50: Gedeon Richter Plc - Women's Infertility Pipeline Portfolio, 2011 65
Table 51: Women's Infertility Therapeutics, Global, Deals, 2009-2011 66
1.2 List of Figures
Figure 1: The Reproduction Process from Ovulation to Implantation 6
Figure 2: Distribution of Cause(s) of Infertility 6
Figure 3: Causes of Women's Infertility 7
Figure 4: Pathophysiology of Infertility 8
Figure 5: Treatment Algorithm for Women's Infertility 10
Figure 6: Women's Infertility Therapeutics, Global, Market Revenue ($m), 2005-2010 13
Figure 7: Women's Infertility Therapeutics, Global, Market Revenue ($m), 2010-2018 14
Figure 8: Women's Infertility Therapeutics Market, The US, Revenue ($m), 2005-2010 15
Figure 9: Women's Infertility Therapeutics Market, The US, Forecast ($m), 2010-2018 16
Figure 10: Women's Infertility Therapeutics Market, France, Revenue ($m), 2005-2010 17
Figure 11: Women's Infertility Therapeutics, France, Revenue Forecasts ($m), 2010-2018 18
Figure 12: Women's Infertility Therapeutics Market, Germany, Revenue ($m), 2005-2010 19
Figure 13: Women's Infertility Therapeutics, Germany, Revenue Forecasts ($m), 2010-2018 20
Figure 14: Women's Infertility Therapeutics, Italy, Market Revenue ($m), 2005-2010 21
Figure 15: Women's Infertility Therapeutics, Italy, Revenue Forecasts ($m), 2010-2018 22
Figure 16: Women's Infertility Therapeutics, Spain, Market Revenue ($m), 2005-2010 23
Figure 17: Women's Infertility Therapeutics, Spain, Revenue Forecasts ($m), 2010-2018 24
Figure 18: Women's Infertility Therapeutics, the UK, Market Revenue ($m), 2005-2010 25
Figure 19: Women's Infertility Therapeutics, the UK, Revenue Forecasts ($m), 2010-2018 26
Figure 20: Women's Infertility Therapeutics, Japan, Market Revenue ($m), 2005-2010 27
Figure 21: Women's Infertility Therapeutics Market, Japan, Forecast ($m), 2010-2018 28
Figure 22: Opportunity and Unmet Need in the Women's Infertility Therapeutic Market, 2010 30
Figure 23: Strategic Competitor Assessment of Marketed Products for Women's Infertility, 2010 31
Figure 24: Women's Infertility Therapeutics - Pipeline by Phase of Development, 2011 42
Figure 25: Women's Infertility Market - Clinical Pipeline by Mechanism of Action, 2011 44
Figure 26: Women's Infertility Therapeutics - Technology Trends Analytics Framework, 2011 45
Figure 27: Women's Infertility Therapeutics - Technology Trends Analytics Framework - Description, 2011 46
Figure 28: Women's Infertility Clinical Trials by Region, 2011 49
Figure 29: Women's Infertility Clinical Trials by Phase, 2011 50
Figure 30: Women's Infertility Therapeutics - Clinical Trials by Status, 2011 51
Figure 31: Women's Infertility Therapeutics - Overall Sponsors, 2011 52
Figure 32: Women's Infertility Therapeutics - Prominent Sponsors, 2011 52
Figure 33: Women's Infertility Therapeutics - Top Companies Participating in Therapeutics Clinical Trials, 2011 54
Figure 34: Women's Infertility Therapeutics, Drivers and Barriers, 2011 55
Figure 35: Implications for Future Market Competition in the Women's Infertility Therapeutics Market, 2011 55
Figure 36: Women's Infertility Therapeutics, Clinical Pipeline by Company, 2011 57
Figure 37: GlobalData Market Forecasting Model 71
Companies mentioned
Merck and Co., Inc.
Dong-A Pharmaceutical Co. Ltd.
Teva Pharmaceutical Industries Limited
Gedeon Richter Plc
To order this report:
Hardware, Home Improvement & Furnishing Stores Industry: Women's Infertility Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Hardware, Home Improvement & Furnishing Stores Business News
Check our Industry Analysis and Insights
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article